NASDAQ:HSGXHistogenics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.31 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$0.30Now: $0.31▼$0.3250-Day Range$0.26MA: $0.33▼$0.4752-Week Range$0.08Now: $0.31▼$1.43Volume11.48 million shsAverage Volume10.71 million shsMarket Capitalization$29.33 millionP/E RatioN/ADividend YieldN/ABeta3.1 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Histogenics. Previous Next 2.8 Community Rank Outperform VotesHistogenics has received 359 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHistogenics has received 284 “underperform” votes. (Add your “underperform” vote.)Community SentimentHistogenics has received 55.83% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote “Outperform” if you believe HSGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHistogenics does not currently pay a dividend.Dividend GrowthHistogenics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Histogenics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 19.70% of the stock of Histogenics is held by insiders.Percentage Held by Institutions40.35% of the stock of Histogenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Histogenics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Histogenics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.76 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSGX Previous Symbol CUSIPN/A CIK1372299 Webwww.histogenics.com Phone781-547-7900Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio4.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-31.00Profitability EPS (Most Recent Fiscal Year)($0.79) Net Income$-8,640,000.00 Net MarginsN/A Return on Equity-34.96% Return on Assets18.40%Miscellaneous Employees49 Outstanding Shares94,600,000Market Cap$29.33 million Next Earnings Date8/7/2020 (Estimated) OptionableNot Optionable NASDAQ:HSGX Rates by TradingView Receive HSGX News and Ratings via Email Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter. Histogenics (NASDAQ:HSGX) Frequently Asked Questions How has Histogenics' stock been impacted by COVID-19 (Coronavirus)? Histogenics' stock was trading at $0.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSGX stock has decreased by 22.5% and is now trading at $0.31. View which stocks have been most impacted by Coronavirus. When is Histogenics' next earnings date? Histogenics is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Histogenics. How were Histogenics' earnings last quarter? Histogenics Corp (NASDAQ:HSGX) posted its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.10. View Histogenics' earnings history. Has Histogenics been receiving favorable news coverage? Media coverage about HSGX stock has been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Histogenics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutHistogenics. Who are some of Histogenics' key competitors? Some companies that are related to Histogenics include Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Ocugen (OCGN), Bionik Laboratories (BNKL), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), NanoVibronix (NAOV) and Avitar (AVTI). View all competitors. What other stocks do shareholders of Histogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Diagnostics Group (IDXG), Novavax (NVAX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Trevena (TRVN), Ocular Therapeutix (OCUL), Opko Health (OPK) and Synergy Pharmaceuticals (SGYP). Who are Histogenics' key executives? Histogenics' management team includes the following people: Mr. Adam D. Gridley, Interim Pres, CEO Treasurer, Sec., Consultant & Director (Age 47)Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 49)Mr. Stephen R. Kennedy, Consultant (Age 62) When did Histogenics IPO? (HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. What is Histogenics' stock symbol? Histogenics trades on the NASDAQ under the ticker symbol "HSGX." How do I buy shares of Histogenics? Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Histogenics' stock price today? One share of HSGX stock can currently be purchased for approximately $0.31. How big of a company is Histogenics? Histogenics has a market capitalization of $29.33 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Histogenics employs 49 workers across the globe. What is Histogenics' official website? The official website for Histogenics is www.histogenics.com. How can I contact Histogenics? Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
